337 related articles for article (PubMed ID: 29322846)
21. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
22. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
23. NUPR1 Silencing Induces Autophagy-Mediated Apoptosis in Multiple Myeloma Cells Through the PI3K/AKT/mTOR Pathway.
Li A; Li X; Chen X; Zeng C; Wang Z; Li Z; Chen J
DNA Cell Biol; 2020 Mar; 39(3):368-378. PubMed ID: 31971825
[TBL] [Abstract][Full Text] [Related]
24. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
[TBL] [Abstract][Full Text] [Related]
25. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Blachly JS; Baiocchi RA
Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
[TBL] [Abstract][Full Text] [Related]
26. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
27. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells.
Martelli AM; Evangelisti C; Follo MY; Ramazzotti G; Fini M; Giardino R; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2011; 18(18):2715-26. PubMed ID: 21649579
[TBL] [Abstract][Full Text] [Related]
28. S6K Promotes Dopaminergic Neuronal Differentiation Through PI3K/Akt/mTOR-Dependent Signaling Pathways in Human Neural Stem Cells.
Lee JE; Lim MS; Park JH; Park CH; Koh HC
Mol Neurobiol; 2016 Aug; 53(6):3771-3782. PubMed ID: 26143260
[TBL] [Abstract][Full Text] [Related]
29. Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro.
Yang Y; Zhou X; Xiao M; Hong Z; Gong Q; Jiang L; Zhou J
J Huazhong Univ Sci Technolog Med Sci; 2010 Dec; 30(6):734-40. PubMed ID: 21181363
[TBL] [Abstract][Full Text] [Related]
30. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
31. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
Nepstad I; Hatfield KJ; Grønningsæter IS; Reikvam H
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326335
[TBL] [Abstract][Full Text] [Related]
32. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
Herschbein L; Liesveld JL
Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
[TBL] [Abstract][Full Text] [Related]
33. α-Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice.
Wang F; Ma H; Liu Z; Huang W; Xu X; Zhang X
Biomed Pharmacother; 2017 Aug; 92():672-680. PubMed ID: 28582759
[TBL] [Abstract][Full Text] [Related]
34. Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma.
Zhu J; Wang M; Cao B; Hou T; Mao X
Curr Med Chem; 2014; 21(27):3173-87. PubMed ID: 24934342
[TBL] [Abstract][Full Text] [Related]
35. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
36. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.
Zhang H; Xu HL; Wang YC; Lu ZY; Yu XF; Sui DY
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614812
[TBL] [Abstract][Full Text] [Related]
37. Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment.
Ahmad A; Biersack B; Li Y; Kong D; Bao B; Schobert R; Padhye SB; Sarkar FH
Anticancer Agents Med Chem; 2013 Sep; 13(7):1014-24. PubMed ID: 23272911
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
Narayanankutty A
Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
[TBL] [Abstract][Full Text] [Related]
39. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
40. [Recent studies on PI3K/AKT/mTOR signaling pathway in hematopoietic stem cells].
Zhang YC; Cheng T; Yuan WP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):245-9. PubMed ID: 23484729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]